Questions in need of answers are evaluation of the influence on growth and rupture by medical treatment and parameters other than absolute diameter for selection of patients for open surgical or endovascular intervention. These questions need not necessarily be answered by randomised controlled trials.
ones (2, 3). Randomised trials in humans were, however,unsuccessful mainly because of low compliance due to severes ide effects by propranolol, the drug used in the trials (4, 5). The findings regarding β -blockers emphasise the need for randomised trials in the evaluation of drug treatment with the goal to diminish AAA growth rate. Such treatment will become morei mportant with increasing numbers of screening programs, which will facilitate the study of candidate drugs.
Matrix metalloproteases (MMP), mainly MMP-2 and -9, aret hought to be of major importance for elastin degeneration in the aortic wall leading to aneurysm expansion. Specific inhibitors have been shown to reduce aortic dilatation in experimental animals. (6), but such drugs aren ot well suited for human use due to side-effects. Tetracyclines have been shown to inhibit matrix metalloproteases, a mechanism which is independent of their antibiotic effect (7) . Some small studies in humans have verified that doxycycline decreases plasma levels of MMP-9 (8) and as mall single centrer andomised study showed decreased growth rate of small AAA in the treatment group (9). Another antibiotic, roxithromycin belonging to the macrolide group has shown similar effects (10) . Treating patients with small AAA with an antibiotic, however,seems less desirable than if drugs usually shown to be of benefit for atherosclerotic disease associated with AAA could have the Many questions regarding treatment of abdominal aortic aneurysm (AAA) ares till unanswered. Two issues of major importance aremedical treatment and selection of patients for intervention. How is it possible to influence growth rate of small AAAs? Are thereb etter ways to select patients with AAA for treatment than the predominantly used method i.e. absolute diameter measurements?
MEDICAl TREATMEnT of PoSSIblE InflUEnCE on gRowTH of AAA Many drugshave been tried based on targets thought to be of importance for AAA development and growth. Most such candidate drugs have initially been tried in animal models of AAA (1).
Retrospective studies have indicated that β -blockers could prevent growth rate of AAA and that selective blockers werel ess effective than nonselective same effect. Twosuch candidate drugs arestatins and angiotensin-II inhibitors.
Statins have been shown to attenuate expansion in elastase induced aneurysms in rats (11) and in hypercholesterolemic mice (12) . Various observational studies indicate that statins influence AAA growth rate. A significantly lower growth rate in statin users has been recorded in patients under surveillance for their small AAA (13, 14) . The mechanism for the influence of statins on AAA growth rate has been related to a pleiotropic effect depending upon the anti-inflammatory effect of the statins, i. e. not related to decreased lipids levels. lower MMP-9 levels wereo bserved in theaortic wallinpatients randomisedto preoperative treatment with simvastatin beforeo pen surgical repair of AAA compared to ac ontrol group (15) . This study,however,was small and had difficulties to recruit patients since most in the target population with AAA already wereo ns tatin treatment because of their associated atherosclerotic disease.
Arandomised control trial to prove the inhibitory effect of statins on aneurysm growth rate may be complicated because of ethical concerns and the fact that many patients with increased aortic diameter will be prescribed statins. AAA is related to atherosclerosis and consequently patients with this disease should be treated with statins (16), particularly since aneurysm diameter is an independent risk factor for cardiovascular death (17, 18) . It is thus possible that astatin trial for patients with AAA will never be performed, although it would be of great value to definitely prove the effect of statins. one way to get out of this dilemma would be ar andomised controlled trial using different dosages of statins to establish a dose response curve.
Angiotensin-II has also been shown to cause aneurysms in experimental animals. Most of these studies have been performed in hyperlipidemic apolipoprotein E-deficient mice receiving infusions of angiotensin-II (19, 20) . The aneurysms developing in animals receiving angiotensin-II have certain differences compared to human AAA. They seem to be localised to the suprarenal part of the aorta and the pathogenesis is linked to dissection.
Alarge cohort study has compared patients admitted to hospital for ruptured or intact AAA receiving angiotensin converting enzyme (ACE) inhibitors or not. Therew eres ignificantly fewer patients who received ACE inhibitors in the ruptured group than in the group that did not receive those inhibitors. This effect was not seen for other drugs used for treatment of hypertension including angiotensin receptor blockers (21) . An interesting finding was that the association between ACE inhibitors and low rate of rupture was not seen among patients who had discontinued their use of prescribed ACE inhibitors shortly before admission to hospital. The findings could be compatible with an effect of ACE inhibitors on risk of ruptureassuch. Astudy about the effect of ACE inhibitors could be performed in as urveillance program within aframework of ascreening program. It is possible that this specific effect of ACE inhibitors on the risk of ruptureisbetter studied in agroup of patients unfit for open repair or EVAR.
EVAlUATIon of PARAMETERS REPlACIng AbSolUTE AnEURySM DIAMETER
It has been shown that patients with AAA diameters ranging between 4-5,5 cm do not benefit from surgical intervention provided that they do not develop symptoms or have agrowth rate exceeding 1cmper year (22, 23) . The normal aortic diameter is related to bodysurface and sex, women having smaller normal diameters. It is thereforep ossible that an ormalised aneurysm diameter related to body surface could be abetter predictor for aneurysm rupturethan absolute diameter (24, 25) and in the case of gender differences this is even likely (26) .
The exact level of an increase in diameter compared to normal diameter for the definition of aneurysm is not established but a5 0% increase has been suggested (24). The normalised diameter at which surgery should be recommended is also not established but could be related to 5.5 cm in an average man. Apossible scenario for such astudy comparing absolute with normalised diameters is surveillance within the framework of screening programs.
Another parameter indicating risk of rupturei s peak wall stress (PwS) as suggested by fillinger and co-workers (27) . The calculation of PwS is based on finite element (fEM) analysis based on CT images, since the geometry of the AAA influences wall stress. The patient's blood pressurei sa lso included in this analysis. It has been suggested that this method is superior to measurements of absolute diameter in identifying patients who area th igh risk of rupture (28) . Cut off-levels for PwSr emain to be analysed, but it has been suggested that 44 n/cm 2 should be a limit. Ac omparison between PwS and absolute diameter could be performed within the framework of asurveillance program of ascreening program.
The ruptureo fa na neurysm, however,i sn ot related only to wall stress but also to wall strength since ruptureoccurs when wall stress exceeds wall strength. Attempts to identify rupturerisk including also wall strength have been made. biomechanical studies have identified four parameters that influence wall strength: normalised diameter,f amily historyo f AAA, gender and the thickness of the intraluminal thrombus (IlT) (29) . for two individuals of the same gender and with identical AAAs the one with family history has aw eaker aneurysm wall amounting to 21 n/cm 2 .C orresponding value for female sex was 19 n/cm 2 .for an increase of the volume of the intraluminal thrombus ad ecrease in strength was noted as well as an increase in normalised diameter.Adding this to afEM analysis of the AAA allows for acalculation of ar upturer isk index (RRI). whether such calculations could add to predictions using only PwS is unknown but with the current development of computerised models it is possible to calculate the RRI.
The comparison between endovascular (EVAR) and open (oR) repair of AAA is based on randomised trials (30, 31) . for patients unfit for open repair this comparison is not possible and such patients were entered into the EVAR-2 Trial (32) . no difference between the groups regarding aneurysm related death and survival was seen in this trial. The study has been as ubject of much debate due to long time between randomisation and EVAR in the intervention group and cross over of patients from the observation group to the intervention group. The results in these two groups could possibly balance each other,which could have contributed to the fact that absence of a difference between the two randomised groups was still present when analysed per protocol. Another subject of criticism is that the procedural mortality rate in the EVAR group was high and that the definition of unfitness for surgery was not robust.
The debate regarding the value of EVAR-2 could be settled by an ew trial with am orer obust parameter defining unfitness for open repair.Ane valuation of fitness for open repair has been done of patients included in the two EVAR Trials using ac ustomised probability index (CPI) (33) . The analysis indicated that unfit for surgery was judged differently in EVAR-1c ompared to EVAR-2 (34). This indicates that it is extremely difficult to construct instruments for risk indices and that individual variation, not included in risk evaluation instruments, may play a role. It is possible that clinical judgement is superior to all methods used to evaluate risk for open surgery,but in the above mentioned study it is clear that this clinical judgement was different in the two trials. These facts speak against an ew trial or at least point to the fact that an ew risk index should be carefully designed beforeanew trial is planned. 
